Solvonis Therapeutics Plc SVNS

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) says new analysis of its ketamine-based alcohol treatment shows patients cut heavy drinking days by 67% compared with placebo, more than four months after their last dose. The company says that puts SVN-001 ahead of naltrexone, sold as Vivitrol,...

Diversified Energy Company PLC (LSE:DEC, NYSE:DEC, FRA:DG20) has agreed its biggest-ever deal, paying $1.8 billion for Permian Basin producer Birch. It should boost production by around 35%. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has landed a £110 million contract to improve water quality in the River Mease. It'll build a 23-kilometre pipeline for Severn Trent. Sunda Energy PLC (AIM:SNDA, FRA:GHA0) has seen a big upgrade at its Halcon prospect offshore the Philippines, now assigned 8 trillion cubic feet of gas resources. That gives Sunda a 3 Tcf net share. Rockfire Resources PLC (LSE:R

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company, has been granted a Notice of Allowance by the European Patent Office for a composition-of-matter patent covering its lead PTSD treatment. The allowance, which the company described as a "vital...

Chesnara PLC (LSE:CSN) saw operating capital generation jump 79% to £96 million in the first half.  CEO Steve Murray also highlighted the group's 185% solvency coverage ratio and an active acquisition pipeline. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to push forward its CNS drug pipeline.  That includes trials for alcohol use disorder and addiction treatments. hVIVO PLC (AIM:HVO) has bought CRS Berlin to expand into dermatology and women's health trials.  The CEO says it opens up new markets and cross-selling opportunities in Germany. Gelion PLC (AIM:GELN, OTC:G

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) CEO Anthony Tennyson spoke with Proactive's Stephen Gunnion about the company's £1.3 million fundraising and how proceeds will support its CNS pipeline, spanning SVN-001, SVN-002 and SVN-015. Tennyson said the funding will let Solvonis assess adding international sites to the Phase 3 programme for SVN-001, its severe alcohol use disorder treatment being trialled within the UK's NHS. Including EU sites and data could improve prospects for a European launch or make the programme more attractive to partners. On SVN-002, developed for moderate to sev

Chesnara PLC (LSE:CSN) is still hunting for acquisitions, with its Scottish Widows Europe deal on track by year end. Reporting back for the first half of its financial year, the company said operating capital generation jumped 79% to £96 million. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to fund three separate treatment programmes. That includes trials targeting alcohol, and methamphetamine and cocaine use disorders. Savannah Energy PLC (AIM:SAVE) says its Uquo 13 well in Nigeria has started producing gas. It's now expecting output to top 20,000 barrels of oil equ

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company developing treatments for addiction and psychiatric disorders, has raised £1.3 million through a share placing. The company is issuing 1.08 billion new shares at 0.12p each. It said the fundraising...

Shares in Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) rose 7% to 0.15p after it cleared the first hurdle in a US government testing programme for an experimental treatment for cocaine and methamphetamine addiction. The National Institute on Drug Abuse, part of the US government's medical...

Water Tower Research has initiated coverage of Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company developing ketamine-based treatments for alcohol use disorder. Analysts framed Solvonis as a late clinical-stage company trading at a microcap valuation...

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) CEO, Anthony Tennyson, talked with Proactive about positive bridging pharmacokinetic (PK) data from the company's SVN-002 programme and what the results mean for its development strategy in alcohol use disorder. Tennyson explained that Solvonis...

Solvonis Therapeutics PLC (LSE, OTC) says new data supports its lead alcohol use disorder programme ahead of a planned Phase 2b trial. CEO Anthony Tennyson says the results could streamline development and open access to a market of around 15 million US adults. Tertiary Minerals PLC (AIM, OTC, FRA) has started its biggest-ever drilling programme in Zambia.  Managing director Richard Belcher says the campaign aims to define a maiden resource while testing for extensions and a potentially deeper sulphide system. CelLBxHealth PLC (AIM, FRA) is reshaping its strategy around cancer diagnostics and

Solvonis Therapeutics (LSE:SVNS) CEO Anthony Tennyson joined Proactive's Stephen Gunnion to discuss positive bridging pharmacokinetic data from the SVN-002 programme and what it means for the company's strategy in alcohol use disorder. Solvonis is advancing SVN-002 toward a Phase 2b trial for moderate to severe alcohol use disorder in the US, repurposing Johnson & Johnson's approved esketamine treatment Spravato via the FDA's 505(b)(2) pathway. Preclinical PK studies showed comparable exposure levels of esketamine and its metabolites via sublingual and buccal delivery compared with intranasal

Eco Buildings Group (AIM:ECOB) has completed the second floor of its first apartment block in Albania, proving its prefab building system works at scale. The block of 18 apartments should bring in around €2.2 million in revenue upon completion, with five more blocks planned. Solvonis Therapeutics (LSE:SVNS) has cleared a key hurdle for its alcohol addiction treatment, showing it delivers the same drug levels as an approved depression medicine. That clears the path towards human trials within the next two years. Coinsilium Group (AQSE:COIN) has made a strategic investment in Predictive Labs, do

Shares in Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), rose 12% to 0.21p after it said it had demonstrated that its experimental alcohol addiction medication releases the active ingredient into the bloodstream at levels comparable to an existing approved depression drug, clearing a...

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) nearly doubled revenues to CHF 77.2 million in 2025, driven by strong AGAMREE sales across Europe.  The company expects to hit cash flow breakeven in Q3 2026 without raising additional capital. AOTI Inc (AIM:AOTI) has published a major study showing its wound oxygen therapy healed 64.8% of patients with chronic wounds that had resisted treatment for an average of seven months.  The study, which involved 3,126-patients, also reported hospitalisation rates of just 3.7% and amputation rates of 6.1%. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF,

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson tells Proactive's Stephen Gunnion that 2025 was a transformational year, marked by the acquisition of Awakn Life Sciences, a strategic rebrand, and a sharp refocus on high-burden CNS disorders. The centrepiece of the conversation is lead programme SVN-001 and the decision to take it through phase III rather than pursue an early licensing deal. Tennyson is direct about the rationale: shareholder value is greater at the end of a successful phase III than before it. Phase II data for SVN-001 in severe alcohol use disorder showed meaningful

MedPal AI plc (AIM:MPAL) has picked up a pharmacy facility in Runcorn for £310,000 from administrators. The site dispensed a million prescription items last year, worth around £10 million in turnover. Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) is shifting its Eroxon business from pure licensing toward a hybrid model with direct sales. It's also progressing two development projects, Eroxon Intense and the WSD4000 female sexual health platform. Solvonis Therapeutics PLC (LSE:SVNS) is pushing its alcohol use disorder drug SVN-001 into phase III trials rather than doing an early licensin

hVIVO PLC (AIM:HVO) has signed its largest-ever human challenge trial contract, testing a whooping cough vaccine for US biotech ILiAD Biotechnologies. The trial will involve more than 500 volunteers and is expected to generate the majority of its revenue across 2026 and 2027. Rift Helium PLC (AIM:RIFT) made a strong debut on AIM, with shares opening 10% above the 10p issue price after raising £8.1 million. The Tanzania-focused explorer is targeting a 19 billion cubic foot helium resource and plans to drill within the next 12 months. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has secured a

Sunda Energy PLC (AIM:SNDA) has made a transformational acquisition in New Zealand, giving it immediate production of over 1,000 barrels a day. The deal adds a third pillar to its portfolio alongside assets in Timor-Leste and the Philippines. Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) has expanded its partnership with TDK Corporation, successfully moving its battery cathode technology into a pouch cell format. TDK dominates the drone battery market, and prototype results are expected soon. Coiled Therapeutics (AIM:COIL) has reported a jump in clinical benefit rate from 40% to 80% for its cancer

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company securing two US patents that significantly strengthen its PTSD treatment program. Tennyson explained that the patents cover two distinct chemical series, reinforcing the company’s intellectual property position and demonstrating that Solvonis is building “a novel chemistry platform and not just a single asset story.” He highlighted that having multiple chemically distinct approaches is critical in CNS drug discovery, increasing the likelihood of identifying compounds with the rig